In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 306 for your search:

Drug:  fludarabine phosphate
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Phase: Phase IV
Type: Treatment
Status: Closed
Age: 16 to 65
Sponsor: Other
Protocol IDs: MCC-14178, NCT00361140

Stem Cell Transplant for Bone Marrow Failure Syndromes

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 35 and under
Sponsor: Other
Protocol IDs: MT2000-18, 9504M09637, NCT00176878

Nonmyeloablative Stem Cell Transplant in Elderly

Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: Over 60
Sponsor: Other
Protocol IDs: 012000, NCT00382759

Phase III Comparison of CLB vs FAMP in Previously Untreated Patients with Intermediate- and High-Risk (Rai Stages I-IV) B-Cell CLL

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CLB-9011, CAN-NCIC-CL1, E-C9011, SWOG-9108, CALGB-9011, CL1

Phase III Randomized Study of Single-Agent FAMP vs CVP (CTX/VCR/PRED) in Previously Untreated Patients with Stage III/IV Low-Grade non-Hodgkin's Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: EORTC-20921

Total-Body Irradiation With Or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Under 75
Sponsor: NCI, Other
Protocol IDs: 1813.00, NCI-2009-01532, P01CA078902, FHCRC-1813.00, 5666, NCT00075478

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CAM314, 2004-000149-39, NCT00086580

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 102-14, BO17072, NCT00090051

Primary Rituximab and Maintenance

Phase: Phase III
Type: Treatment
Status: Completed
Age: over 18
Sponsor: Other
Protocol IDs: PRIMA, NCT00140582

10.

Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia

Phase: Phase III
Type: Treatment
Status: Completed
Age: 17 and under
Sponsor: Other
Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966

11.

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDR0000454560, GCLLSG-CLL-8, EU-20560, ML17102, GCLLSG-CLL-8/ML17/02, NCT00281918

12.

Phase III Randomized Study of Risk-Adapted Therapy With Fludarabine Versus Observation Only in Patients With Stage 0-II B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL1, EU-20548, GCLLSG-138, MEDAC-GCLLSG-CLL1, NCT00262782

13.

Phase III Randomized Study of Fludarabine Versus Chlorambucil as First-Line Therapy in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 to 79
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL5, EU-20557, MEDAC-GCLLSG-CLL5, GCLLSG-73, NCT00262795

14.

Phase III Randomized Study of Fludarabine With Versus Without Cyclophosphamide in Patients With Previously Untreated Advanced Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL4, EU-20538, GCLLSG-153, ISRCTN75653261, MEDAC-GCLLSG-CLL4, NCT00276848

15.

Phase III Randomized Study of Fludarabine, Mitoxantrone Hydrochloride, and Cyclophosphamide With Versus Without Filgrastim (G-CSF) in Patients With Relapsed Binet Stage B or C Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: GCLLSG-CLL6, EU-20558, AMGEN-GCLLSG-CLL6, MEDAC-GCLLSG-CLL6, NCT00416910

16.

Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NIP-03-007, NCT00254163

17.

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1992.00, NCI-2010-00737, P01CA078902, K23HL084054, P01CA018029, P01HL036444, FHCRC-1992.00, 6170, NHLBI-K23-HL084054-01A1, NCT00322101

18.

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000537685, U10CA031946, CALGB-10501, NCT00513747

19.

Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 1 to 21
Sponsor: NCI, NHLBI
Protocol IDs: 467, BMT CTN 0501, 5 U01 HL69294-05, FHCRC-2128.00, NCT00412360

20.

IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and under
Sponsor: Other
Protocol IDs: 2005-0366, NCT00469144

21.

Phase III Randomized Study of Fludarabine Phosphate and Rituximab With Versus Without Pixantrone in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTI-CRRI-0807003, CRRI 0807003, NCT00551239

22.

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000577580, CLL-2007-FMP, INCA-RECF0496, EudraCT-2007-000327-18, RECF0496, NCT00564512

23.

Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old

Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: CHUBX 2007/13, NCT00590837

24.

FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: CDR0000616169, GCLLSG-CLL10, 2007-007587-21, CLL10, EUDRACT-2007-007587-21, EU-20883, ROCHE-GCLLSG-CLL10, NCT00769522

25.

Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen